Novo Nordisk

LATEST NEWS: Novo Nordisk

Novo Nordisk as of 7 May 2026

increased its 2026 guidance after stronger-than-expected American demand for its oral Wegovy obesity treatment boosted quarterly revenue.

Novo Nordisk as of 20 April 2026:

🧬 Major breakthrough in sickle cell disease

Novo Nordisk reported strong Phase 3 results for its drug etavopivat:

The drug met both primary endpoints in the HIBISCUS trial

Reduced severe pain crises by ~27% and significantly improved haemoglobin levels

A regulatory filing is planned for late 2026

👉 This is a major expansion beyond Novo’s core diabetes/obesity focus into hematology, putting pressure on competitors in the space.

💰 Ongoing share buyback programme

Novo continues its DKK 15 billion share repurchase programme launched in February 2026

By mid-April, it had already repurchased over 12 million shares worth ~DKK 3.1 billion

👉 This signals confidence in long-term value despite market volatility.

🤖 Strategic shift: AI partnership

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

The goal is to speed up the development of new treatments and improve efficiency

This comes as Novo faces increasing competition in obesity drugs, especially from rivals like Eli Lilly

🧭 What it means

Novo is diversifying beyond obesity and diabetes into new therapeutic areas

Heavy investment in AI and innovation to regain a competitive edge

Maintaining shareholder returns while navigating pricing pressure and competition

Bottom line

As of 20 April 2026, Novo Nordisk is in a transition phase:

strong pipeline progress (especially in sickle cell disease), combined with a strategic push into AI and continued financial discipline.